eli lilly tirzepatide fda approval Lilly's Zepbound (aka tirzepatide) Lands for Weight Loss FDA approves Eli Lilly's obesity

The WHO released its first global guideline for GLP-1 obesity treatment, recognizing obesity as a chronic disease

Conclusion Semaglutide confers robust cardiovascular protection in T2D, with amplified benefits in patients with comorbid CKD

Nonetheless, whether semaglutide holds efficacy as both an antidepressant and anxiolytic agent remains uncertain

Program key points: Semiglutide is a medication that is injected into the subcutaneous fat of your belly, behind your arm, or inner thigh once a week

Learn what research reveals about GLP-1 effects on energy expenditure.

This broader mechanism provides metabolic benefits that extend beyond glucose control and appetite suppression